Database Query Results : Artemisinin, ,

ART/DHA, Artemisinin: Click to Expand ⟱
Features:
Artemisinin a compound in a Chinese herb that may inhibit tumor growth and metastasis Artemisinin (antimalarial drugs)
Artesunic acid (Artesunate) , Dihydroartemisinin (DHA), artesunate, arteether, and artemether, SM735, SM905, SM933, SM934, and SM1044

The induction of OS in tumor cells via the production of ROS is the key mechanism of ART against cancer.
combination of ART and Nrf2 inhibitors to promote ferroptosis may have more efficient anticancer effects without damaging normal cells.

Summary:
- One of the strongest tumor-selective pro-oxidants, mechanism related with iron. Synergizes with iron-rich tumors
-ROS seems to affect both cancer and normal cells
- Delivery of artemisinin in conjugate form with transferrin or holotransferrin (serum iron transport proteins) have been shown to greatly improve its effectiveness.
- Potential direct inhibitor of STAT3
- Artemisinin synergized with the glycolysis inhibitor 2DG (2-deoxy- D -glucose)
ART Combined Therapy: Allicin, Resveratrol, Curcumin, VitC (but not orally at same time), Butyrate , 2-DG, Aminolevulinic AcidG
-possible problems with liver toxicity??

-Artesunate (ART), an artemisinin compound, is known for lysosomal degradation of ferritin, inducing oxidative stress and promoting cancer cell death.

Pathways:
- Increasing reactive oxygen species (ROS) production. This oxidative stress can cause the loss of mitochondrial membrane potential, leading to cytochrome c release and subsequent activation of caspase cascades.
- Downregulate HIF-1α
- By impairing glycolysis, artemisinin might force cells to rely on oxidative phosphorylation (OXPHOS) for energy production.
- Inhibit GLUT1 (glucose uptake), HK2, PKM2 (slow the glycolytic flux, thereby reducing the energy supply)
- Minimal NRF2 activation

-Artemisinin has a half-life of about 3-4 hours, Artesunate 40 minutes and Artemether 12 hours. Peak plasma levels occur in 1-2 hour.
BioAv 21%, poor-good solubility. Artesunate (ART), a water soluble derivative of artemisinin. concentrations higher in blood, colon, liver, kidney (highly perfused organs)
Pathways:
- induce ROS production, iron dependent (affect both cancer and normal cells)
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓,
- Both Lowers (and raises) AntiOxidant defense in Cancer Cells: NRF2↓(contary), SOD↓, GSH↓ Catalase↓ GPx↓
- Small evidence of Raising AntiOxidant defense in Normal Cells: ROS↓(contary), NRF2↑, SOD↑(contary), GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : NLRP3↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, TIMP2, IGF-1↓, uPA↓, VEGF↓, ROCK1↓, NF-κB↓, TGF-β↓, ERK↓
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, ERK↓, EMT↓, TOP1↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, ECAR↓, GRP78↑, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, EGFR↓, Integrins↓,
- some small indication of inhibiting Cancer Stem Cells : CSC↓, Hh↓, β-catenin↓, sox2↓, OCT4↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, ERK↓, JNK,
- Synergies: chemo-sensitization, RadioSensitizer, Others(review target notes),

- Selectivity: Cancer Cells vs Normal Cells
Often synergistic with ROS-based chemo
Scientific Papers found: Click to Expand⟱
2577- ART/DHA,    Artemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectives
- Review, Var, NA
"highlight2" >eff↑, "highlight2" >TumCCA↑, "highlight2" >BioAv↑, "highlight2" >eff↑, "highlight2" >ChemoSen↑,
3385- ART/DHA,    Interaction of artemisinin protects the activity of antioxidant enzyme catalase: A biophysical study
- Study, NA, NA
"highlight2" >*NF-kB↑, "highlight2" >*Catalase↑,
3384- ART/DHA,    Dihydroartemisinin triggers ferroptosis in primary liver cancer cells by promoting and unfolded protein response‑induced upregulation of CHAC1 expression
- in-vitro, Liver, Hep3B - in-vitro, Liver, HUH7 - in-vitro, Liver, HepG2
"highlight2" >Ferroptosis↑, "highlight2" >ROS↑, "highlight2" >GSH↓, "highlight2" >UPR↑, "highlight2" >GPx4↓, "highlight2" >PERK↑, "highlight2" >eIF2α↑, "highlight2" >ATF4↑,
3383- ART/DHA,    Dihydroartemisinin: A Potential Natural Anticancer Drug
- Review, Var, NA
"highlight2" >TumCP↓, "highlight2" >Apoptosis↑, "highlight2" >TumMeta↓, "highlight2" >angioG↓, "highlight2" >TumAuto↑, "highlight2" >ER Stress↑, "highlight2" >ROS↑, "highlight2" >Ca+2↑, "highlight2" >p38↑, "highlight2" >HSP70/HSPA5↓, "highlight2" >PPARγ↑, "highlight2" >GLUT1↓, "highlight2" >Glycolysis↓, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >Hif1a↓, "highlight2" >PKM2↓, "highlight2" >lactateProd↓, "highlight2" >GlucoseCon↓, "highlight2" >EMT↓, "highlight2" >Slug↓, "highlight2" >Zeb1↓, "highlight2" >ZEB2↓, "highlight2" >Twist↓, "highlight2" >Snail?, "highlight2" >CAFs/TAFs↓, "highlight2" >TGF-β↓, "highlight2" >p‑STAT3↓, "highlight2" >M2 MC↓, "highlight2" >uPA↓, "highlight2" >HH↓, "highlight2" >AXL↓, "highlight2" >VEGFR2↓, "highlight2" >JNK↑, "highlight2" >Beclin-1↑, "highlight2" >GRP78/BiP↑, "highlight2" >eff↑, "highlight2" >eff↑, "highlight2" >eff↑, "highlight2" >eff↑, "highlight2" >eff↑, "highlight2" >eff↑, "highlight2" >IL4↓, "highlight2" >DR5↑, "highlight2" >Cyt‑c↑, "highlight2" >Fas↑, "highlight2" >FADD↑, "highlight2" >cl‑PARP↑, "highlight2" >cycE/CCNE↓, "highlight2" >CDK2↓, "highlight2" >CDK4↓, "highlight2" >Mcl-1↓, "highlight2" >Ki-67↓, "highlight2" >Bcl-2↓, "highlight2" >CDK6↓, "highlight2" >VEGF↓, "highlight2" >COX2↓, "highlight2" >MMP9↓,
3382- ART/DHA,    Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?
- Review, Var, NA
"highlight2" >AntiCan↑, "highlight2" >toxicity↑, "highlight2" >Ferroptosis↑, "highlight2" >ROS↑, "highlight2" >TumCCA↑, "highlight2" >BioAv↝, "highlight2" >eff↝, "highlight2" >Half-Life↓, "highlight2" >Ferritin↓, "highlight2" >GPx4↓, "highlight2" >NADPH↓, "highlight2" >GSH↓, "highlight2" >BAX↑, "highlight2" >Cyt‑c↑, "highlight2" >cl‑Casp3↑, "highlight2" >VEGF↓, "highlight2" >IL8↓, "highlight2" >COX2↓, "highlight2" >MMP9↓, "highlight2" >E-cadherin↑, "highlight2" >MMP2↓, "highlight2" >NF-kB↓, "highlight2" >p16↑, "highlight2" >CDK4↓, "highlight2" >cycD1/CCND1↓, "highlight2" >p62↓, "highlight2" >LC3II↑, "highlight2" >EMT↓, "highlight2" >CSCs↓, "highlight2" >Wnt↓, "highlight2" >β-catenin/ZEB1↓, "highlight2" >uPA↓, "highlight2" >TumAuto↑, "highlight2" >angioG↓, "highlight2" >ChemoSen↑,
3345- ART/DHA,    Dihydroartemisinin-induced unfolded protein response feedback attenuates ferroptosis via PERK/ATF4/HSPA5 pathway in glioma cells
- in-vitro, GBM, NA
"highlight2" >ROS↑, "highlight2" >Ferroptosis↑, "highlight2" >lipid-P↑, "highlight2" >HSP70/HSPA5↑, "highlight2" >ER Stress↑, "highlight2" >ATF4↑, "highlight2" >GRP78/BiP↑, "highlight2" >MDA↑, "highlight2" >GSH↓, "highlight2" >eff↑, "highlight2" >GPx4↑,
2582- ART/DHA,  5-ALA,    Mechanistic Investigation of the Specific Anticancer Property of Artemisinin and Its Combination with Aminolevulinic Acid for Enhanced Anticolorectal Cancer Activity
- in-vivo, CRC, HCT116 - in-vitro, CRC, HCT116
"highlight2" >eff↑, "highlight2" >ROS↑, "highlight2" >selectivity↑, "highlight2" >TumCG↓, "highlight2" >toxicity↓,
2581- ART/DHA,  PB,    Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells
- in-vitro, AML, NA
"highlight2" >eff↑, "highlight2" >selectivity↑,
2580- ART/DHA,  VitC,    Effects of Antioxidants and Pro-oxidants on Cytotoxicity of Dihydroartemisinin to Molt-4 Human Leukemia Cells
- in-vitro, AML, NA
"highlight2" >eff↓, "highlight2" >other↝, "highlight2" >ROS↑, "highlight2" >eff↓, "highlight2" >eff↓,
2578- ART/DHA,  RES,    Synergic effects of artemisinin and resveratrol in cancer cells
- in-vitro, Liver, HepG2 - in-vitro, Cerv, HeLa
"highlight2" >Dose↝, "highlight2" >TumCMig↓, "highlight2" >Apoptosis↑, "highlight2" >necrosis↑, "highlight2" >ROS↑, "highlight2" >eff↑,
3386- ART/DHA,    Effects of Caffeine-Artemisinin Combination on Liver Function and Oxidative Stress in Selected Organs in 7,12-Dimethylbenzanthracene-Treated Rats
- in-vivo, Nor, NA
"highlight2" >*MDA↑, "highlight2" >*SOD↓, "highlight2" >*GSH∅, "highlight2" >*Catalase↓,
2576- ART/DHA,  AL,    The Synergistic Anticancer Effect of Artesunate Combined with Allicin in Osteosarcoma Cell Line in Vitro and in Vivo
- in-vitro, OS, MG63 - in-vivo, NA, NA
"highlight2" >eff↑, "highlight2" >tumCV↓, "highlight2" >Casp3↑, "highlight2" >Casp9↑, "highlight2" >Apoptosis↑, "highlight2" >TumCG↓,
2575- ART/DHA,  docx,    Artemisia santolinifolia-Mediated Chemosensitization via Activation of Distinct Cell Death Modes and Suppression of STAT3/Survivin-Signaling Pathways in NSCLC
- in-vitro, Lung, H23
"highlight2" >ChemoSen↑, "highlight2" >GPx4↓, "highlight2" >ROS↑, "highlight2" >Ferroptosis↑, "highlight2" >eff↑,
2574- ART/DHA,    Artemisinin: A Promising Adjunct for Cancer Therapy
- Review, Var, NA
"highlight2" >selectivity↑, "highlight2" >eff↑,
2573- ART/DHA,    Cell death mechanisms induced by synergistic effects of halofuginone and artemisinin in colorectal cancer cells
- in-vitro, CRC, HCT116
"highlight2" >eff↑,
2572- ART/DHA,  SRF,    Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax
- in-vitro, AML, NA
"highlight2" >CHOP↑, "highlight2" >Mcl-1↓, "highlight2" >ChemoSen↑, "highlight2" >selectivity↑,
2571- ART/DHA,    Cancer combination therapies with artemisinin-type drugs
- Review, Var, NA
"highlight2" >AntiTum↑, "highlight2" >ChemoSen↑, "highlight2" >hepatoP↝,
2570- ART/DHA,    Discovery, mechanisms of action and combination therapy of artemisinin
- Review, Nor, NA
"highlight2" >*BioAv↓, "highlight2" >*Half-Life↓, "highlight2" >*toxicity↓, "highlight2" >*ROS↑, "highlight2" >GSH↓, "highlight2" >selectivity↑,
555- ART/DHA,    Artemisinin as an anticancer drug: Recent advances in target profiling and mechanisms of action
- Review, NA, NA
"highlight2" >STAT3↓,
3395- ART/DHA,    Artesunate Induces Ferroptosis in Hepatic Stellate Cells and Alleviates Liver Fibrosis via the ROCK1/ATF3 Axis
- in-vitro, NA, HSC-T6
"highlight2" >*Ferroptosis↑, "highlight2" >*GSH↓, "highlight2" >*ROCK1↓,
4993- ART/DHA,    Dihydroartemisinin inhibits galectin-1–induced ferroptosis resistance and peritoneal metastasis of gastric cancer via the Nrf2–HO-1 pathway
- vitro+vivo, GC, NA
"highlight2" >Ferroptosis↑, "highlight2" >NRF2↓, "highlight2" >HO-1↓, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >TumMeta↓,
4992- ART/DHA,    Dihydroartemisinin Increases the Sensitivity of Acute Myeloid Leukemia Cells to Cytarabine via the Nrf2/HO-1 Anti-Oxidant Signaling Pathway
- in-vitro, AML, HL-60
"highlight2" >Apoptosis↑, "highlight2" >Diff↑, "highlight2" >ROS↓, "highlight2" >HO-1↓, "highlight2" >NRF2∅,
4991- ART/DHA,  doxoR,    Dihydroartemisinin alleviates doxorubicin-induced cardiotoxicity and ferroptosis by activating Nrf2 and regulating autophagy
- in-vivo, Nor, H9c2
"highlight2" >*cardioP↑, "highlight2" >*ROS↓, "highlight2" >*Ferroptosis↓, "highlight2" >*NRF2↑, "highlight2" >Keap1↓,
4278- ART/DHA,    Artemisinin Ameliorates the Neurotoxic Effect of 3-Nitropropionic Acid: A Possible Involvement of the ERK/BDNF/Nrf2/HO-1 Signaling Pathway
- in-vivo, NA, NA
"highlight2" >*IL6↓, "highlight2" >*Casp3↓, "highlight2" >*Casp9↓, "highlight2" >*BDNF↑, "highlight2" >*ERK↑, "highlight2" >*NRF2↑, "highlight2" >*HO-1↑, "highlight2" >*neuroP↑, "highlight2" >*antiOx↑, "highlight2" >*Inflam↓,
3667- ART/DHA,    Artemisinin improves neurocognitive deficits associated with sepsis by activating the AMPK axis in microglia
- Review, Sepsis, NA
"highlight2" >*cognitive↑, "highlight2" >*neuroP↑, "highlight2" >*TNF-α↓, "highlight2" >*IL6↓, "highlight2" >*NF-kB↓, "highlight2" >*AMPK↑, "highlight2" >*ROS↓, "highlight2" >*Akt↑, "highlight2" >*MCP1↓, "highlight2" >*MIP2↓, "highlight2" >*TGF-β↑, "highlight2" >*Inflam↓,
3666- ART/DHA,    Artemisinin Attenuates Amyloid-Induced Brain Inflammation and Memory Impairments by Modulating TLR4/NF-κB Signaling
- NA, AD, NA
"highlight2" >*Inflam↓, "highlight2" >*neuroP↑, "highlight2" >*TLR4↓, "highlight2" >*NF-kB↓, "highlight2" >*memory↑, "highlight2" >*ROS↓, "highlight2" >*iNOS↓, "highlight2" >*COX2↓, "highlight2" >*cognitive↑,
3665- ART/DHA,    Artemisinin B Improves Learning and Memory Impairment in AD Dementia Mice by Suppressing Neuroinflammation
- Review, AD, NA
"highlight2" >*Inflam↓, "highlight2" >*NO↓, "highlight2" >*IL1β↓, "highlight2" >*IL6↓, "highlight2" >*TNF-α↓, "highlight2" >*MyD88↓, "highlight2" >*NF-kB↓, "highlight2" >*TLR4↓, "highlight2" >*memory↑,
3396- ART/DHA,    Progress on the study of the anticancer effects of artesunate
- Review, Var, NA
"highlight2" >TumCP↓, "highlight2" >TumCI↓, "highlight2" >TumCMig↓, "highlight2" >Apoptosis↑, "highlight2" >Diff↑, "highlight2" >TumAuto↑, "highlight2" >angioG↓, "highlight2" >TumCCA↑, "highlight2" >ROS↑, "highlight2" >AMPK↑, "highlight2" >mTOR↑, "highlight2" >ChemoSen↑, "highlight2" >Tf↑, "highlight2" >Ferroptosis↑, "highlight2" >Ferritin↓, "highlight2" >lipid-P↑, "highlight2" >CDK1↑, "highlight2" >CDK2↑, "highlight2" >CDK4↑, "highlight2" >CDK6↑, "highlight2" >SIRT1↑, "highlight2" >COX2↓, "highlight2" >IL1β↓, "highlight2" >survivin↓, "highlight2" >DNAdam↑, "highlight2" >RadioS↑,
2569- ART/DHA,    A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction
- Human, Nor, NA
"highlight2" >*Half-Life↝, "highlight2" >BioAv↝, "highlight2" >*Half-Life↓, "highlight2" >BioAv↑, "highlight2" >*Dose↝,
3394- ART/DHA,    Anticancer activities and mechanisms of heat-clearing and detoxicating traditional Chinese herbal medicine
"highlight2" >IGF-1R↓,
3393- ART/DHA,    Artemisinin-derived artemisitene blocks ROS-mediated NLRP3 inflammasome and alleviates ulcerative colitis
- in-vivo, Col, NA
"highlight2" >*ROS↓, "highlight2" >*NLRP3↓, "highlight2" >*Inflam↓,
3392- ART/DHA,    Artemisinin inhibits inflammatory response via regulating NF-κB and MAPK signaling pathways
- in-vitro, Nor, Hep3B - in-vivo, NA, NA
"highlight2" >*Inflam↓, "highlight2" >*NF-kB↓, "highlight2" >*ROS↓, "highlight2" >*p‑p38↓, "highlight2" >*p‑ERK↓,
3391- ART/DHA,    Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug
- Review, Var, NA
"highlight2" >TumCP↓, "highlight2" >TumMeta↓, "highlight2" >angioG↓, "highlight2" >TumVol↓, "highlight2" >BioAv↓, "highlight2" >Half-Life↓, "highlight2" >BioAv↑, "highlight2" >eff↑, "highlight2" >eff↓, "highlight2" >ROS↑, "highlight2" >selectivity↑, "highlight2" >TumCCA↑, "highlight2" >survivin↓, "highlight2" >BAX↑, "highlight2" >Casp3↓, "highlight2" >Casp8↑, "highlight2" >Casp9↑, "highlight2" >CDC25↓, "highlight2" >CycB/CCNB1↓, "highlight2" >NF-kB↓, "highlight2" >cycD1/CCND1↓, "highlight2" >cycE/CCNE↓, "highlight2" >E2Fs↓, "highlight2" >P21↑, "highlight2" >p27↑, "highlight2" >ADP:ATP↑, "highlight2" >MDM2↓, "highlight2" >VEGF↓, "highlight2" >IL8↓, "highlight2" >COX2↓, "highlight2" >MMP9↓, "highlight2" >ER Stress↓, "highlight2" >cMyc↓, "highlight2" >GRP78/BiP↑, "highlight2" >DNAdam↑, "highlight2" >AP-1↓, "highlight2" >MMP2↓, "highlight2" >PKCδ↓, "highlight2" >Raf↓, "highlight2" >ERK↓, "highlight2" >JNK↓, "highlight2" >PCNA↓, "highlight2" >CDK2↓, "highlight2" >CDK4↓, "highlight2" >TOP2↓, "highlight2" >uPA↓, "highlight2" >MMP7↓, "highlight2" >TIMP2↑, "highlight2" >Cdc42↑, "highlight2" >E-cadherin↑,
3390- ART/DHA,    Ferroptosis: The Silver Lining of Cancer Therapy
"highlight2" >Ferroptosis↑, "highlight2" >Iron↑, "highlight2" >NCOA4↝, "highlight2" >ROS↑, "highlight2" >Fenton↑, "highlight2" >Tf↓,
3389- ART/DHA,    Emerging mechanisms and applications of ferroptosis in the treatment of resistant cancers
- Review, Var, NA
"highlight2" >GSH↓, "highlight2" >ROS↑, "highlight2" >NRF2↑, "highlight2" >eff↑,
3388- ART/DHA,    Keap1 Cystenine 151 as a Potential Target for Artemisitene-Induced Nrf2 Activation
- in-vitro, Lung, A549 - in-vitro, Nor, GP-293 - in-vitro, BC, MDA-MB-231
"highlight2" >NRF2↑, "highlight2" >ROS∅,
3387- ART/DHA,    Ferroptosis: A New Research Direction of Artemisinin and Its Derivatives in Anti-Cancer Treatment
- Review, Var, NA
"highlight2" >BioAv↓, "highlight2" >lipid-P↑, "highlight2" >Ferroptosis↑, "highlight2" >Iron↑, "highlight2" >GPx4↓, "highlight2" >GSH↓, "highlight2" >P53↑, "highlight2" >ER Stress↑, "highlight2" >PERK↑, "highlight2" >ATF4↑, "highlight2" >GRP78/BiP↑, "highlight2" >CHOP↑, "highlight2" >ROS↑, "highlight2" >NRF2↑,
564- ART/DHA,  Cisplatin,    Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling
- in-vitro, NA, HN30
"highlight2" >JAK2↓, "highlight2" >STAT3↓, "highlight2" >MMP2↓, "highlight2" >MMP9↓, "highlight2" >Mcl-1↓, "highlight2" >Bcl-xL↓, "highlight2" >cycD1/CCND1↓, "highlight2" >VEGF↓, "highlight2" >TumCCA↑, "highlight2" >ChemoSen↑,
2324- ART/DHA,    Research Progress of Warburg Effect in Hepatocellular Carcinoma
- Review, Var, NA
"highlight2" >PKM2↓, "highlight2" >GLUT1↓, "highlight2" >Glycolysis↓, "highlight2" >Akt↓, "highlight2" >mTOR↓, "highlight2" >Hif1a↓, "highlight2" >HK2↓, "highlight2" >LDH↓, "highlight2" >NF-kB↓,
572- ART/DHA,    High-throughput screening identifies artesunate as selective inhibitor of cancer stemness: Involvement of mitochondrial metabolism
"highlight2" >CSCs↓, "highlight2" >mtDam↑,
571- ART/DHA,  TMZ,    Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence
- vitro+vivo, GBM, A172 - vitro+vivo, GBM, U87MG
"highlight2" >HR↓, "highlight2" >RAD51↓, "highlight2" >Apoptosis↑, "highlight2" >necrosis↑, "highlight2" >ROS↑, "highlight2" >ChemoSen↑,
570- ART/DHA,    Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling
- vitro+vivo, NSCLC, A549 - vitro+vivo, NSCLC, H1299
"highlight2" >TumCCA↑, "highlight2" >CSCs↓, "highlight2" >TumCI↓, "highlight2" >TumCMig↓, "highlight2" >TumCG↓, "highlight2" >Wnt/(β-catenin)↓, "highlight2" >Nanog↓, "highlight2" >SOX2↓, "highlight2" >OCT4↓, "highlight2" >N-cadherin↓, "highlight2" >Vim↓, "highlight2" >E-cadherin↑,
569- ART/DHA,    Dihydroartemisinin exhibits anti-glioma stem cell activity through inhibiting p-AKT and activating caspase-3
- in-vitro, GBM, NA
"highlight2" >TumCP↓, "highlight2" >Apoptosis↑, "highlight2" >TumCCA↑, "highlight2" >Casp3↑, "highlight2" >p‑Akt↓,
568- ART/DHA,    Mechanism-Guided Design and Synthesis of a Mitochondria-Targeting Artemisinin Analogue with Enhanced Anticancer Activity
- in-vitro, NA, MDA-MB-231 - in-vitro, NA, HeLa - in-vitro, NA, SkBr3 - in-vitro, NA, HCT116
"highlight2" >Iron↝,
567- ART/DHA,    An Untargeted Proteomics and Systems-based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells
- in-vitro, Lung, BEAS-2B
"highlight2" >NRF2↑, "highlight2" >AP-1↑, "highlight2" >NFAT↑,
566- ART/DHA,  2DG,    Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells
- in-vitro, Lung, A549 - in-vitro, Lung, PC9
"highlight2" >GlucoseCon↓, "highlight2" >ATP↓, "highlight2" >lactateProd↓, "highlight2" >p‑S6↓, "highlight2" >mTOR↓, "highlight2" >GLUT1↓, "highlight2" >Casp9↑, "highlight2" >Casp8↑, "highlight2" >Casp3↑, "highlight2" >Cyt‑c↑, "highlight2" >AIF↑, "highlight2" >ROS↑,
565- ART/DHA,    Artesunate as an Anti-Cancer Agent Targets Stat-3 and Favorably Suppresses Hepatocellular Carcinoma
"highlight2" >STAT↓, "highlight2" >IL6↓, "highlight2" >pro‑Casp3↝, "highlight2" >Bcl-xL↝, "highlight2" >survivin↝,
573- ART/DHA,    Artesunate suppresses tumor growth and induces apoptosis through the modulation of multiple oncogenic cascades in a chronic myeloid leukemia xenograft mouse model
- vitro+vivo, NA, NA
"highlight2" >p‑p38↓, "highlight2" >p‑ERK↓, "highlight2" >p‑CREB↓, "highlight2" >p‑Chk2↓, "highlight2" >p‑STAT5↓, "highlight2" >p‑RSK↓, "highlight2" >SOCS1↑, "highlight2" >Apoptosis↑, "highlight2" >Casp3↑,
563- ART/DHA,    Artesunate down-regulates immunosuppression from colorectal cancer Colon26 and RKO cells in vitro by decreasing transforming growth factor β1 and interleukin-10
- in-vitro, Colon, colon26 - in-vitro, CRC, RKO
"highlight2" >TGF-β↓, "highlight2" >IL10↓,
562- ART/DHA,    Artesunate exerts an anti-immunosuppressive effect on cervical cancer by inhibiting PGE2 production and Foxp3 expression
- in-vivo, NA, HeLa
"highlight2" >CD4+↓, "highlight2" >CD25+↓, "highlight2" >FoxP3+↓, "highlight2" >Treg lymp↓, "highlight2" >PGE2↓, "highlight2" >FOXP3↓, "highlight2" >COX2↓,
561- ART/DHA,    Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+ CD25+ FoxP3+ T reg cells in vivo
- in-vivo, NA, NA
"highlight2" >TumCG↓, "highlight2" >CD4+↓, "highlight2" >CD25+↓, "highlight2" >FoxP3+↓, "highlight2" >IL4↑,
560- ART/DHA,    Dihydroartemisinin shift the immune response towards Th1, inhibit the tumor growth in vitro and in vivo
- in-vivo, NA, NA
"highlight2" >IL4↓, "highlight2" >CD4+↓, "highlight2" >CD25+↓, "highlight2" >FoxP3+↓, "highlight2" >Treg lymp↓,
559- ART/DHA,    Artemisinin and its derivatives: a promising cancer therapy
- Review, NA, NA
"highlight2" >ROS↑,
558- ART/DHA,    Artemisinin and Its Synthetic Derivatives as a Possible Therapy for Cancer
- Review, NA, NA
"highlight2" >ROS↑, "highlight2" >oncosis↑, "highlight2" >Apoptosis↑, "highlight2" >LysoPr↑, "highlight2" >TumAuto↑, "highlight2" >Wnt/(β-catenin)↑, "highlight2" >AMP↓, "highlight2" >NF-kB↓, "highlight2" >Myc↓, "highlight2" >CREBBP↓, "highlight2" >mTOR↓, "highlight2" >E-cadherin↑,
557- ART/DHA,    Artemisinin and Its Derivatives in Cancer Care
- Review, Var, NA
"highlight2" >*BioAv↓, "highlight2" >*BioAv↑, "highlight2" >Apoptosis↑, "highlight2" >EGFR↓, "highlight2" >CD31↓, "highlight2" >Ki-67↓, "highlight2" >P53↓, "highlight2" >TfR1/CD71↑, "highlight2" >P-gp↓, "highlight2" >PD-1↝,
556- ART/DHA,    Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
- Review, NA, NA
"highlight2" >IL6↓, "highlight2" >IL1↓, "highlight2" >TNF-α↓, "highlight2" >TGF-β↓, "highlight2" >NF-kB↓, "highlight2" >MIP2↓, "highlight2" >PGE2↓, "highlight2" >NO↓, "highlight2" >Hif1a↓, "highlight2" >KDR/FLK-1↓, "highlight2" >VEGF↓, "highlight2" >MMP2↓, "highlight2" >TIMP2↑, "highlight2" >ITGB1↑, "highlight2" >NCAM↑, "highlight2" >p‑ATM↑, "highlight2" >p‑ATR↑, "highlight2" >p‑CHK1↑, "highlight2" >p‑Chk2↑, "highlight2" >Wnt/(β-catenin)↓, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >ERK↓, "highlight2" >cMyc↓, "highlight2" >mTOR↓, "highlight2" >survivin↓, "highlight2" >cMET↓, "highlight2" >EGFR↓, "highlight2" >cycD1/CCND1↓, "highlight2" >cycE1↓, "highlight2" >CDK4/6↓, "highlight2" >p16↑, "highlight2" >p27↑, "highlight2" >Apoptosis↑, "highlight2" >TumAuto↑, "highlight2" >Ferroptosis↑, "highlight2" >oncosis↑, "highlight2" >TumCCA↑, "highlight2" >ROS↑, "highlight2" >DNAdam↑, "highlight2" >RAD51↓, "highlight2" >HR↓,
1076- ART/DHA,    The Potential Mechanisms by which Artemisinin and Its Derivatives Induce Ferroptosis in the Treatment of Cancer
- Review, NA, NA
"highlight2" >Ferroptosis↑, "highlight2" >ROS↑, "highlight2" >ER Stress↑, "highlight2" >i-Iron↓, "highlight2" >TumAuto↑, "highlight2" >AMPK↑, "highlight2" >mTOR↑, "highlight2" >P70S6K↑, "highlight2" >Fenton↑, "highlight2" >lipid-P↑, "highlight2" >ROS↑, "highlight2" >ChemoSen↑, "highlight2" >NRF2↑, "highlight2" >NRF2↓,
2323- ART/DHA,    Dihydroartemisinin represses esophageal cancer glycolysis by down-regulating pyruvate kinase M2
- in-vitro, ESCC, Eca109 - in-vitro, ESCC, EC9706
"highlight2" >PKM2↓, "highlight2" >lactateProd↓, "highlight2" >GlucoseCon↓, "highlight2" >cycD1/CCND1↓, "highlight2" >Bcl-2↓, "highlight2" >MMP2↓, "highlight2" >VEGF↓, "highlight2" >Casp3↑, "highlight2" >cl‑PARP↑, "highlight2" >BAX↑, "highlight2" >DNAdam↑, "highlight2" >ROS↑,
2322- ART/DHA,    Dihydroartemisinin Regulates Self-Renewal of Human Melanoma-Initiating Cells by Targeting PKM2/LDHARelated Glycolysis
- in-vitro, Melanoma, NA
"highlight2" >TumCP↓, "highlight2" >PKM2↓, "highlight2" >LDHA↓, "highlight2" >Glycolysis↓,
2321- ART/DHA,    Dihydroartemisinin mediating PKM2-caspase-8/3-GSDME axis for pyroptosis in esophageal squamous cell carcinoma
- in-vitro, ESCC, Eca109 - in-vitro, ESCC, EC9706
"highlight2" >Pyro↑, "highlight2" >PKM2↓, "highlight2" >Casp8↑, "highlight2" >Casp3↑, "highlight2" >Warburg↓, "highlight2" >TumCCA↑, "highlight2" >Apoptosis↑,
2320- ART/DHA,    Dihydroartemisinin Inhibits the Proliferation of Leukemia Cells K562 by Suppressing PKM2 and GLUT1 Mediated Aerobic Glycolysis
- in-vitro, AML, K562 - in-vitro, Liver, HepG2
"highlight2" >Glycolysis↓, "highlight2" >GlucoseCon↓, "highlight2" >lactateProd↓, "highlight2" >GLUT1↓, "highlight2" >PKM2↓, "highlight2" >ECAR↓, "highlight2" >LDHA↓, "highlight2" >cMyc↓, "highlight2" >other↝,
1148- ART/DHA,    Artemisinin inhibits extracellular matrix metalloproteinase inducer (EMMPRIN) and matrix metalloproteinase-9 expression via a protein kinase Cδ/p38/extracellular signal-regulated kinase pathway in phorbol myristate acetate-induced THP-1 macrophages
- in-vitro, AML, THP1
"highlight2" >MMP9↓, "highlight2" >EMMPRIN↓, "highlight2" >p‑PKCδ↓, "highlight2" >p‑JNK↓, "highlight2" >p‑p38↓, "highlight2" >p‑ERK↓,
1147- ART/DHA,    Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1
- vitro+vivo, Ovarian, HO-8910 - vitro+vivo, Nor, HUVECs
"highlight2" >angioG↓, "highlight2" >TumCG↓, "highlight2" >VEGF↓, "highlight2" >KDR/FLK-1↓, "highlight2" >*toxicity↓,
1099- ART/DHA,    Dihydroartemisinin inhibits IL-6-induced epithelial–mesenchymal transition in laryngeal squamous cell carcinoma via the miR-130b-3p/STAT3/β-catenin signaling pathway
- in-vitro, NA, NA
"highlight2" >EMT↓, "highlight2" >TumCI↓, "highlight2" >STAT3↓, "highlight2" >β-catenin/ZEB1↓,
1079- ART/DHA,    Artesunate inhibits the growth and induces apoptosis of human gastric cancer cells by downregulating COX-2
- in-vitro, GC, BGC-823 - in-vitro, GC, HGC27 - in-vitro, GC, MGC803
"highlight2" >TumCP↓, "highlight2" >Apoptosis↑, "highlight2" >COX2↓, "highlight2" >BAX↑, "highlight2" >Bcl-2↓, "highlight2" >Casp3↑, "highlight2" >Casp9↑, "highlight2" >MMP↓,
574- ART/DHA,    Dihydroartemisinin suppresses glioma proliferation and invasion via inhibition of the ADAM17 pathway
"highlight2" >TumCP↓, "highlight2" >TumCMig↓, "highlight2" >TumCI↓, "highlight2" >MMP17↓, "highlight2" >p‑EGFR↓, "highlight2" >p‑Akt↓,
1075- ART/DHA,    Artemisinin derivatives inactivate cancer-associated fibroblasts through suppressing TGF-β signaling in breast cancer
- in-vitro, Nor, L929
"highlight2" >*TGF-β↓,
1074- ART/DHA,    Artemisinin attenuates lipopolysaccharide-stimulated proinflammatory responses by inhibiting NF-κB pathway in microglia cells
- in-vitro, Nor, BV2
"highlight2" >*TNF-α↓, "highlight2" >*IL6↓, "highlight2" >*MCP1↓, "highlight2" >*NO↓, "highlight2" >*iNOS↓, "highlight2" >*IκB↑,
1026- ART/DHA,    Artemisinin improves the efficiency of anti-PD-L1 therapy in T-cell lymphoma
"highlight2" >Ferroptosis↑, "highlight2" >ROS↑, "highlight2" >ERK↓, "highlight2" >PD-L1↓,
985- ART/DHA,    Artemisinin suppresses aerobic glycolysis in thyroid cancer cells by downregulating HIF-1a, which is increased by the XIST/miR-93/HIF-1a pathway
- in-vitro, Thyroid, TPC-1 - Human, NA, NA
"highlight2" >XIST↓, "highlight2" >Hif1a↓, "highlight2" >Glycolysis↓, "highlight2" >TumCCA↑, "highlight2" >TumMeta↓,
976- ART/DHA,    Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells
- in-vitro, BC, MCF-7
"highlight2" >ERα/ESR1↓,
957- ART/DHA,    Artemisinin inhibits the development of esophageal cancer by targeting HIF-1α to reduce glycolysis levels
- in-vitro, ESCC, KYSE150 - in-vitro, ESCC, KYSE170
"highlight2" >TumCP↓, "highlight2" >TumMeta↓, "highlight2" >Glycolysis↓, "highlight2" >N-cadherin↓, "highlight2" >PKM2↓, "highlight2" >Hif1a↓,
576- ART/DHA,    Profiling of Multiple Targets of Artemisinin Activated by Hemin in Cancer Cell Proteome
- Analysis, NA, NA
"highlight2" >GSTP1/GSTπ↓, "highlight2" >TfR1/CD71↓,
575- ART/DHA,    Dihydroartemisinin initiates ferroptosis in glioblastoma through GPX4 inhibition
- in-vitro, GBM, U87MG
"highlight2" >GPx4↓, "highlight2" >xCT∅, "highlight2" >ROS↑, "highlight2" >Ferroptosis↑, "highlight2" >ACSL4∅,
2579- CUR,  ART/DHA,    Curcumin-Artemisinin Combination Therapy for Malaria
- in-vivo, NA, NA
"highlight2" >OS↑, "highlight2" >toxicity↓,
4438- SNP,  ART/DHA,    Biogenic synthesis of AgNPs using Artemisia oliveriana extract and their biological activities for an effective treatment of lung cancer
- in-vitro, Lung, A549
"highlight2" >EPR↑, "highlight2" >BAX↑, "highlight2" >Bcl-2↑, "highlight2" >Casp3↑, "highlight2" >Casp9↑, "highlight2" >DNAdam↑, "highlight2" >TumCCA↑, "highlight2" >Apoptosis↑,
4552- SNP,  ART/DHA,    Green synthesis of silver nanoparticles using Artemisia turcomanica leaf extract and the study of anti-cancer effect and apoptosis induction on gastric cancer cell line (AGS)
- in-vitro, GC, AGS
"highlight2" >AntiCan↑, "highlight2" >Apoptosis↑, "highlight2" >eff↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 77

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Fenton↑, 2,   Ferroptosis↑, 12,   GPx4↓, 5,   GPx4↑, 1,   GSH↓, 6,   GSTP1/GSTπ↓, 1,   HO-1↓, 2,   Iron↑, 2,   Iron↝, 1,   i-Iron↓, 1,   Keap1↓, 1,   lipid-P↑, 4,   MDA↑, 1,   NRF2↓, 2,   NRF2↑, 5,   NRF2∅, 1,   ROS↓, 1,   ROS↑, 23,   ROS∅, 1,   xCT∅, 1,  

Metal & Cofactor Biology ⓘ

Ferritin↓, 2,   NCOA4↝, 1,   Tf↓, 1,   Tf↑, 1,   TfR1/CD71↓, 1,   TfR1/CD71↑, 1,  

Mitochondria & Bioenergetics ⓘ

ADP:ATP↑, 1,   AIF↑, 1,   ATP↓, 1,   CDC25↓, 1,   MMP↓, 1,   mtDam↑, 1,   Raf↓, 1,  

Core Metabolism/Glycolysis ⓘ

ACSL4∅, 1,   AMP↓, 1,   AMPK↑, 2,   cMyc↓, 3,   p‑CREB↓, 1,   ECAR↓, 1,   GlucoseCon↓, 4,   Glycolysis↓, 6,   HK2↓, 1,   lactateProd↓, 4,   LDH↓, 1,   LDHA↓, 2,   NADPH↓, 1,   PKM2↓, 7,   PPARγ↑, 1,   p‑S6↓, 1,   SIRT1↑, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 4,   p‑Akt↓, 2,   Apoptosis↑, 15,   BAX↑, 5,   Bcl-2↓, 3,   Bcl-2↑, 1,   Bcl-xL↓, 1,   Bcl-xL↝, 1,   Casp3↓, 1,   Casp3↑, 8,   cl‑Casp3↑, 1,   pro‑Casp3↝, 1,   Casp8↑, 3,   Casp9↑, 5,   p‑Chk2↓, 1,   p‑Chk2↑, 1,   Cyt‑c↑, 3,   DR5↑, 1,   FADD↑, 1,   Fas↑, 1,   Ferroptosis↑, 12,   JNK↓, 1,   JNK↑, 1,   p‑JNK↓, 1,   Mcl-1↓, 3,   MDM2↓, 1,   Myc↓, 1,   necrosis↑, 2,   oncosis↑, 2,   p27↑, 2,   p38↑, 1,   p‑p38↓, 2,   Pyro↑, 1,   p‑RSK↓, 1,   survivin↓, 3,   survivin↝, 1,  

Transcription & Epigenetics ⓘ

other↝, 2,   tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 2,   eIF2α↑, 1,   ER Stress↓, 1,   ER Stress↑, 4,   GRP78/BiP↑, 4,   HSP70/HSPA5↓, 1,   HSP70/HSPA5↑, 1,   PERK↑, 2,   UPR↑, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   LC3II↑, 1,   p62↓, 1,   TumAuto↑, 6,  

DNA Damage & Repair ⓘ

p‑ATM↑, 1,   p‑ATR↑, 1,   p‑CHK1↑, 1,   DNAdam↑, 5,   HR↓, 2,   p16↑, 2,   P53↓, 1,   P53↑, 1,   cl‑PARP↑, 2,   PCNA↓, 1,   RAD51↓, 2,  

Cell Cycle & Senescence ⓘ

CDK1↑, 1,   CDK2↓, 2,   CDK2↑, 1,   CDK4↓, 3,   CDK4↑, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 5,   cycE/CCNE↓, 2,   cycE1↓, 1,   E2Fs↓, 1,   P21↑, 1,   TumCCA↑, 11,  

Proliferation, Differentiation & Cell State ⓘ

cMET↓, 1,   CREBBP↓, 1,   CSCs↓, 3,   Diff↑, 2,   EMT↓, 3,   ERK↓, 3,   p‑ERK↓, 2,   HH↓, 1,   IGF-1R↓, 1,   mTOR↓, 4,   mTOR↑, 2,   Nanog↓, 1,   OCT4↓, 1,   P70S6K↑, 1,   PI3K↓, 3,   SOX2↓, 1,   STAT↓, 1,   STAT3↓, 3,   p‑STAT3↓, 1,   p‑STAT5↓, 1,   TOP2↓, 1,   TumCG↓, 5,   Wnt↓, 1,   Wnt/(β-catenin)↓, 2,   Wnt/(β-catenin)↑, 1,  

Migration ⓘ

AP-1↓, 1,   AP-1↑, 1,   AXL↓, 1,   Ca+2↑, 1,   CAFs/TAFs↓, 1,   CD31↓, 1,   Cdc42↑, 1,   CDK4/6↓, 1,   E-cadherin↑, 4,   EMMPRIN↓, 1,   ITGB1↑, 1,   Ki-67↓, 2,   LysoPr↑, 1,   MMP17↓, 1,   MMP2↓, 5,   MMP7↓, 1,   MMP9↓, 5,   N-cadherin↓, 2,   NCAM↑, 1,   NFAT↑, 1,   PKCδ↓, 1,   p‑PKCδ↓, 1,   Slug↓, 1,   Snail?, 1,   TGF-β↓, 3,   TIMP2↑, 2,   Treg lymp↓, 2,   TumCI↓, 4,   TumCMig↓, 4,   TumCP↓, 8,   TumMeta↓, 5,   Twist↓, 1,   uPA↓, 3,   Vim↓, 1,   Zeb1↓, 1,   ZEB2↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 5,   ATF4↑, 3,   EGFR↓, 2,   p‑EGFR↓, 1,   EPR↑, 1,   Hif1a↓, 5,   KDR/FLK-1↓, 2,   NO↓, 1,   VEGF↓, 7,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

GLUT1↓, 4,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

CD25+↓, 3,   CD4+↓, 3,   COX2↓, 6,   FOXP3↓, 1,   FoxP3+↓, 3,   IL1↓, 1,   IL10↓, 1,   IL1β↓, 1,   IL4↓, 2,   IL4↑, 1,   IL6↓, 2,   IL8↓, 2,   JAK2↓, 1,   M2 MC↓, 1,   MIP2↓, 1,   NF-kB↓, 5,   PD-1↝, 1,   PD-L1↓, 1,   PGE2↓, 2,   SOCS1↑, 1,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 1,   CDK6↑, 1,   ERα/ESR1↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 3,   BioAv↝, 2,   ChemoSen↑, 9,   Dose↝, 1,   eff↓, 4,   eff↑, 19,   eff↝, 1,   Half-Life↓, 2,   RadioS↑, 1,   selectivity↑, 6,  

Clinical Biomarkers ⓘ

EGFR↓, 2,   p‑EGFR↓, 1,   ERα/ESR1↓, 1,   Ferritin↓, 2,   IL6↓, 2,   Ki-67↓, 2,   LDH↓, 1,   Myc↓, 1,   PD-L1↓, 1,   XIST↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 2,   AntiTum↑, 1,   hepatoP↝, 1,   OS↑, 1,   toxicity↓, 2,   toxicity↑, 1,   TumVol↓, 1,  
Total Targets: 251

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Catalase↓, 1,   Catalase↑, 1,   Ferroptosis↓, 1,   Ferroptosis↑, 1,   GSH↓, 1,   GSH∅, 1,   HO-1↑, 1,   MDA↑, 1,   NRF2↑, 2,   ROS↓, 5,   ROS↑, 1,   SOD↓, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,  

Cell Death ⓘ

Akt↑, 1,   Casp3↓, 1,   Casp9↓, 1,   Ferroptosis↓, 1,   Ferroptosis↑, 1,   iNOS↓, 2,   p‑p38↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↑, 1,   p‑ERK↓, 1,  

Migration ⓘ

ROCK1↓, 1,   TGF-β↓, 1,   TGF-β↑, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 2,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL1β↓, 1,   IL6↓, 4,   Inflam↓, 6,   IκB↑, 1,   MCP1↓, 2,   MIP2↓, 1,   MyD88↓, 1,   NF-kB↓, 4,   NF-kB↑, 1,   TLR4↓, 2,   TNF-α↓, 3,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 1,   Dose↝, 1,   Half-Life↓, 2,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

IL6↓, 4,  

Functional Outcomes ⓘ

cardioP↑, 1,   cognitive↑, 2,   memory↑, 2,   neuroP↑, 3,   toxicity↓, 2,  
Total Targets: 52

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:34  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page